HT Partners LLC decreased its stake in Eli Lilly and Co. (NYSE:LLY) by 32.3% during the third quarter, Holdings Channel reports. The institutional investor owned 5,089 shares of the company’s stock after selling 2,427 shares during the period. Eli Lilly and comprises approximately 0.2% of HT Partners LLC’s investment portfolio, making the stock its 12th largest position. HT Partners LLC’s holdings in Eli Lilly and were worth $408,000 at the end of the most recent reporting period.
Several other hedge funds have also recently bought and sold shares of the company. City Holding Co. increased its stake in Eli Lilly and by 6.5% in the third quarter. City Holding Co. now owns 29,787 shares of the company’s stock valued at $2,391,000 after buying an additional 1,805 shares in the last quarter. Ronna Sue Cohen boosted its position in Eli Lilly and by 0.3% in the third quarter. Ronna Sue Cohen now owns 2,722 shares of the company’s stock valued at $218,000 after buying an additional 9 shares during the last quarter. Nadler Financial Group Inc. bought a new position in Eli Lilly and during the third quarter valued at approximately $213,000. Bremer Trust National Association boosted its position in Eli Lilly and by 72.1% in the third quarter. Bremer Trust National Association now owns 6,046 shares of the company’s stock valued at $485,000 after buying an additional 2,532 shares during the last quarter. Finally, Triangle Securities Wealth Management bought a new position in Eli Lilly and during the third quarter valued at approximately $894,000. 75.11% of the stock is owned by institutional investors and hedge funds.
Shares of Eli Lilly and Co. (NYSE:LLY) traded up 1.65% on Friday, hitting $69.12. 8,620,682 shares of the stock traded hands. Eli Lilly and Co. has a 1-year low of $64.18 and a 1-year high of $88.16. The stock has a 50 day moving average of $76.69 and a 200-day moving average of $77.92. The stock has a market cap of $73.11 billion, a PE ratio of 30.07 and a beta of 0.28.
Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, October 25th. The company reported $0.88 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.96 by $0.08. The business earned $5.19 billion during the quarter, compared to the consensus estimate of $4.23 billion. Eli Lilly and had a net margin of 11.73% and a return on equity of 23.71%. The company’s revenue was up 4.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.89 EPS. On average, equities research analysts expect that Eli Lilly and Co. will post $3.55 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 9th. Stockholders of record on Tuesday, November 15th will be given a $0.51 dividend. The ex-dividend date is Thursday, November 10th. This represents a $2.04 dividend on an annualized basis and a dividend yield of 2.95%. Eli Lilly and’s payout ratio is presently 88.70%.
Several research firms recently commented on LLY. Citigroup Inc. reiterated a “buy” rating on shares of Eli Lilly and in a research note on Wednesday, August 3rd. Argus upped their target price on shares of Eli Lilly and from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Tuesday, August 2nd. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $93.00 target price for the company in a research note on Friday, July 29th. Leerink Swann reiterated a “buy” rating and set a $103.00 target price on shares of Eli Lilly and in a research note on Sunday, October 9th. Finally, BMO Capital Markets reiterated a “buy” rating and set a $94.00 target price on shares of Eli Lilly and in a research note on Monday, October 3rd. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $108.95.
In related news, insider Maria A. Crowe sold 2,248 shares of the business’s stock in a transaction dated Wednesday, October 5th. The stock was sold at an average price of $81.37, for a total value of $182,919.76. Following the completion of the transaction, the insider now owns 94,319 shares of the company’s stock, valued at $7,674,737.03. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.20% of the stock is currently owned by insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.